Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes

Csaba Mátyás, Balázs T. Németh, A. Oláh, Marianna Török, Mihály Ruppert, Dalma Kellermayer, Bálint A. Barta, G. Szabó, Gábor Kökény, Eszter M. Horváth, Beáta Bódi, Z. Papp, B. Merkely, Tamás Radovits

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aims: Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A) inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF. Methods and results: Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals received vehicle or 10 mg/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology was assessed by left ventricular (LV) pressure–volume analysis and echocardiography at week 32. Cardiomyocyte force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis, myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased LV/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively prevented the development of HFpEF by maintaining diastolic function (decreased LV/cardiomyocyte stiffness and LV relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative stress, myocardial hypertrophy and fibrotic remodelling. Conclusions: We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus, PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with diabetes mellitus.

Original languageEnglish
Pages (from-to)326-336
Number of pages11
JournalEuropean Journal of Heart Failure
Volume19
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Phosphodiesterase Inhibitors
Type 2 Diabetes Mellitus
Heart Failure
Cyclic GMP
Cardiac Myocytes
Diabetic Cardiomyopathies
Cyclic GMP-Dependent Protein Kinases
Oxidative Stress
Apoptosis
Hypertrophy
Diabetes Mellitus
Guanylate Kinases
Left Ventricular Dysfunction
Vardenafil Dihydrochloride
Left Ventricular Function
Echocardiography
Myocardium
Fibrosis
Cardiovascular Diseases

Keywords

  • Cardiomyocyte stiffness
  • cGMP
  • Diabetic cardiomyopathy
  • Diastolic dysfunction
  • Vardenafil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. / Mátyás, Csaba; Németh, Balázs T.; Oláh, A.; Török, Marianna; Ruppert, Mihály; Kellermayer, Dalma; Barta, Bálint A.; Szabó, G.; Kökény, Gábor; Horváth, Eszter M.; Bódi, Beáta; Papp, Z.; Merkely, B.; Radovits, Tamás.

In: European Journal of Heart Failure, Vol. 19, No. 3, 01.03.2017, p. 326-336.

Research output: Contribution to journalArticle

Mátyás, Csaba ; Németh, Balázs T. ; Oláh, A. ; Török, Marianna ; Ruppert, Mihály ; Kellermayer, Dalma ; Barta, Bálint A. ; Szabó, G. ; Kökény, Gábor ; Horváth, Eszter M. ; Bódi, Beáta ; Papp, Z. ; Merkely, B. ; Radovits, Tamás. / Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. In: European Journal of Heart Failure. 2017 ; Vol. 19, No. 3. pp. 326-336.
@article{893ec1811ab943b59c15531bdd49a6aa,
title = "Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes",
abstract = "Aims: Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A) inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF. Methods and results: Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals received vehicle or 10 mg/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology was assessed by left ventricular (LV) pressure–volume analysis and echocardiography at week 32. Cardiomyocyte force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis, myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased LV/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively prevented the development of HFpEF by maintaining diastolic function (decreased LV/cardiomyocyte stiffness and LV relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative stress, myocardial hypertrophy and fibrotic remodelling. Conclusions: We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus, PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with diabetes mellitus.",
keywords = "Cardiomyocyte stiffness, cGMP, Diabetic cardiomyopathy, Diastolic dysfunction, Vardenafil",
author = "Csaba M{\'a}ty{\'a}s and N{\'e}meth, {Bal{\'a}zs T.} and A. Ol{\'a}h and Marianna T{\"o}r{\"o}k and Mih{\'a}ly Ruppert and Dalma Kellermayer and Barta, {B{\'a}lint A.} and G. Szab{\'o} and G{\'a}bor K{\"o}k{\'e}ny and Horv{\'a}th, {Eszter M.} and Be{\'a}ta B{\'o}di and Z. Papp and B. Merkely and Tam{\'a}s Radovits",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/ejhf.711",
language = "English",
volume = "19",
pages = "326--336",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes

AU - Mátyás, Csaba

AU - Németh, Balázs T.

AU - Oláh, A.

AU - Török, Marianna

AU - Ruppert, Mihály

AU - Kellermayer, Dalma

AU - Barta, Bálint A.

AU - Szabó, G.

AU - Kökény, Gábor

AU - Horváth, Eszter M.

AU - Bódi, Beáta

AU - Papp, Z.

AU - Merkely, B.

AU - Radovits, Tamás

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Aims: Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A) inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF. Methods and results: Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals received vehicle or 10 mg/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology was assessed by left ventricular (LV) pressure–volume analysis and echocardiography at week 32. Cardiomyocyte force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis, myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased LV/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively prevented the development of HFpEF by maintaining diastolic function (decreased LV/cardiomyocyte stiffness and LV relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative stress, myocardial hypertrophy and fibrotic remodelling. Conclusions: We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus, PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with diabetes mellitus.

AB - Aims: Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A) inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF. Methods and results: Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals received vehicle or 10 mg/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology was assessed by left ventricular (LV) pressure–volume analysis and echocardiography at week 32. Cardiomyocyte force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis, myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased LV/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively prevented the development of HFpEF by maintaining diastolic function (decreased LV/cardiomyocyte stiffness and LV relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative stress, myocardial hypertrophy and fibrotic remodelling. Conclusions: We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus, PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with diabetes mellitus.

KW - Cardiomyocyte stiffness

KW - cGMP

KW - Diabetic cardiomyopathy

KW - Diastolic dysfunction

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=85007236091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007236091&partnerID=8YFLogxK

U2 - 10.1002/ejhf.711

DO - 10.1002/ejhf.711

M3 - Article

C2 - 27995696

AN - SCOPUS:85007236091

VL - 19

SP - 326

EP - 336

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -